Watchful waiting vs repair for asymptomatic or minimally symptomatic inguinal hernia in men: a systematic review

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Purpose: One-third of patients presenting with inguinal hernia are asymptomatic and the best treatment for these patients is unclear. The aim of this study was to assess the feasibility of applying a watchful waiting strategy for asymptomatic or minimally symptomatic inguinal hernia in men. Methods: PubMed, EMBASE, and Cochrane Library were searched from database inception to May 14, 2020. Included were all types of original data written in English, German, Danish, Swedish, or Norwegian involving ≥ 5 male patients aged ≥ 18 years old with asymptomatic or minimally symptomatic inguinal hernia and undergoing watchful waiting. This review was reported according to the PRISMA guideline. Results: A total of nine studies were included; three randomized controlled trials, three prospective cohort studies, and three retrospective cohort studies. Data on a total of 858 unique patients following a watchful waiting strategy were included. Approximately one-third of patients crossed over from watchful waiting to surgery after 3 years increasing to more than two-thirds after 10 years. The most frequent reason for crossover was hernia-related pain (median 79%, range 48–91%). The rate of acute hernia-related operations was low (2–3%), and watchful waiting was not associated with increased mortality or postoperative complications. Levels of pain and discomfort after randomization were similar over time between patients undergoing elective repair or watchful waiting. Conclusion: Applying a watchful waiting strategy to men with asymptomatic or minimally symptomatic inguinal hernia was safe, but two-thirds of patients crossed over to surgical repair within 10 years mainly due to pain.

OriginalsprogEngelsk
TidsskriftHernia
Vol/bind25
Udgave nummer5
Sider (fra-til)1121-1128
ISSN1265-4906
DOI
StatusUdgivet - 2021

Bibliografisk note

Publisher Copyright:
© 2020, Springer-Verlag France SAS, part of Springer Nature.

ID: 271619466